FDA approves VisionCare’s telescope implant for AMD

October 28, 2014

The U.S. Food and Drug Administration approved VisionCare Ophthalmic Technologies’ implantable miniature telescope for use in patients living with bilateral end-stage age-related macular degeneration (AMD) who are age 65 or older.

Saratoga, CA-The U.S. Food and Drug Administration approved VisionCare Ophthalmic Technologies’ implantable miniature telescope for use in patients living with bilateral end-stage age-related macular degeneration (AMD) who are age 65 or older. The telescope implant is the only FDA approved surgical device for end-stage AMD and is Medicare eligible.

Current views on genetic testing for AMD

According to the company, the telescope implant improves visual acuity and quality of life for suitable patients with AMD whose sight is permanently obstructed by a blind spot in their central vision, making it difficult or impossible to see faces, read, and perform everyday activities such as watching TV, preparing meals, and self-care.

“Despite all the great pharmacotherapy advances in AMD treatment, some patients will unfortunately progress to end-stage AMD where their straight ahead, central vision is permanently blocked,” said Dr. David Boyer, of Retina Vitreous Associates Medical Group, Beverly Hills, CA. “Once end-stage AMD patients have lost their central vision, cataract surgery will not provide them with as much benefit to their quality of life as the telescope implant.”

The telescope implant is not a cure for end-stage AMD. According to the company, possible side effects include decreased vision or vision impairing corneal swelling.